Inventiva S.A.
EPA:IVA.PA
Overview | Financials
Company Name | Inventiva S.A. |
Symbol | IVA.PA |
Currency | EUR |
Price | 2.45 |
Market Cap | 212,912,095 |
Dividend Yield | 0% |
52-week-range | 1.434 - 4.44 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Frederic Cren |
Website | https://www.inventivapharma.com |
An error occurred while fetching data.
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD